Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad COO Andrew Last to retire by early September 2024; search for successor underway

Neutral Impact 4 of 5 leadership Written later

Bio-Rad Laboratories' Executive Vice President and Chief Operating Officer, Dr. Andrew Last, notified the company on April 10, 2024 that he plans to retire by early September 2024. He will stay in his current role while Bio-Rad searches for a successor, which the company says is intended to ensure a smooth transition.

Key points

  • Dr. Andrew Last, EVP and Chief Operating Officer, intends to retire by early September 2024
  • Dr. Last will remain in his current position while the company searches for a successor
  • Dr. Last joined Bio-Rad in April 2019; CEO Norman Schwartz credited him with cost structure, core process and supply chain improvements

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECApr 10, 2024, 4:16 PM ET
Accession number0000012208-24-000025

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 10, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.